Citigroup Upgrades Bio-Techne to Buy, Raises Price Target to $100

Citigroup analyst Patrick Donnelly upgrades Bio-Techne (NASDAQ:TECH) from Neutral to Buy and raises the price target from $81.25 to $100.

Citigroup analyst Patrick Donnelly upgrades Bio-Techne (NASDAQ:TECH) from Neutral to Buy and raises the price target from $81.25 to $100.

Total
0
Shares
Related Posts